Stockreport

MAIA Biotechnology Highlights Ongoing Momentum of Ateganosine Clinical Program at SITC 2025

MAIA Biotechnology, Inc.  (MAIA) 
PDF Company confirms 12 patients enrolled in Phase 2 THIO-101 to date as expansion trial adds new countries Posters for Phase 2 and Phase 3 clinical trials available CHICA [Read more]